Lung Cancer: Lung Cancer III |

Clinical Experience on Treatment of Advanced Lung Adenocarcinoma With Unknown EGFR Gene Status From a Tertiary Care Center in China FREE TO VIEW

YuLong Zheng; Xin Xu; Cheng Xiao; ChengYu Mao; Jiong Qian; HaiPing Jiang; Jing Deng; Nong Xu
Author and Funding Information

Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;149(4_S):A314. doi:10.1016/j.chest.2016.02.327
Text Size: A A A
Published online


SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: Limited data are available on treatment experience in patients with advanced lung adenocarcinoma with unknown EGFR gene status (UN-EGFR-GS). We studied the demographic profile and treatment outcomes of advanced NSCLC patients with adenocarcinoma, which the EGFR gene status was unknown.

METHODS: Retrospective study of patients with UN-EGFR-GS advanced lung adenocarcinoma over a 5-year period at a tertiary care institute in China. Patients diagnosed with stage IIIB or IV were included for analysis during 2009 and 2013. And the efficacy of EGFR-TKIs in advanced NSCLC was evaluated in patients with UN-EGFR-GS.

RESULTS: In total, 113 patients were included, 95.6% of whom had stage IV disease. Thirty six patients received gemcitabine plus platinum as the first-line treatment, 32 received pemetrexed plus platinum, 11 received EGFR-TKIs and the rest received docetaxel, paclitaxel, novelbine and etc. Forty four patients received oral EGFR-TKIs as the second-line treatment. At the end of follow-up (2015-3-30), 91 patients were dead and 22 patients were alive or lost follow up. The median survival of this whole cohort was 20.0m (95%CI, 16.1m-24.0m,). The overall survival was not associated with the chemotherapy drugs used in the first-line treatment. The patients (19.0m, 95%CI; 11.4m-26.5m) used pemetrexed plus platinum lived no longer than those who used other regimens (20.5m, 95%CI; 13.4m-27.4m) (p=0.272). In the gemcitabine plus platinum group, the median survival was 19.9m (95%CI; 9.2m-30.6m), which was not longer than other groups (20.0m, 95%CI; 15.4m-27.4m) (p=0.404). Those who had a chance to take EGFR-TKIs lived numerically longer than never; the median survival was 24.8m (19.1m-30.5m, 95%CI) and 16.3m (12.7m-19.9m, 95%CI), respectively. However, the overall difference was not significant (p=0.184).

CONCLUSIONS: The median survival of patients with advanced lung adenocarcinoma with UN-EGFR-GS was 20m. Oral EGFR-TKIs appear to be useful for this group of patients.

CLINICAL IMPLICATIONS: EGFR-TKIs showed to be the oppotunity for the advanced lung adenocarcinoma patients with UN-EGFR-GS.

DISCLOSURE: The following authors have nothing to disclose: YuLong Zheng, Xin Xu, Cheng Xiao, ChengYu Mao, Jiong Qian, HaiPing Jiang, Jing Deng, Nong Xu

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543